Questions discussed in this category
Would you offer them as second line?
Do you drop or adjust the temozolomide at any point, or rather continue to progression as long as temozolomide is well tolerated?
What would your approach be in a patient with a mid-esophageal squamous cell carcinoma treated with chemoradiation therapy followed by surgery, with P...
Would you consider switching to a different regimen?
Would you consider the BEACON regimen (i.e., encorafenib/binimetinib + cetuximab) in this setting?
Which patients would you recommend active surveillance alone, a less morbid procedure such as enucleation, or a Whipple surgery? How does age influenc...
Total neoadjuvant therapy (TNT) included FOLFOX x 4 months and concurrent chemo-RT
Does the patient's young age affect your decision when applying data from the IDEA collaboration?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
If so, how many cycles would you give? Both the MAGIC and FLOT trials showed difficulty with administering adjuvant chemotherapy.
Do the overall survival results of PARADIGM presented at ASCO 2022 change the standard of care?
If you do not use prophylaxis, what skin care strategy do you employ?
Would you give trastuzumab every 2 or 3 weeks, pembrolizumab every 3 or 6 weeks?
Would you debulk with neoadjuvant therapy to achieve resectability?
Would you consider gem+Abraxane to avoid FOLFIRINOX toxicity in a small, node-negative tumor?
Residual GEJ mass and progression in local lymph nodes after carbo+taxol chemoRT without distant metastases.
If so, would you adjust 5-FU dosing?
Would your thinking change if the patient continues to be NED after an unplanned chemo break, e.g. for insurance issues?
Is it necessary to test CPS given the FDA approvals are not contingent on CPS %?
If you do test, do you check 28-8 (nivolumab), 22C3 (pembroliz...
Would you use reduced dose chemoimmunotherapy, single agent chemotherapy, or single agent immunotherapy if the patient is unlikely to tolerate full do...
Do you view CPS < 1% or 1-4% separately? Do you view the incremental benefit of adding immunotherapy still advantageous given relatively poor outco...
Do you go by FDA approval alone, or incorporate other data into your treatment decisions? How do you view updated recent presentation of CM-649 ...
Are there meaningful differences in the CHECKMATE 649 and KEYNOTE 590 studies to guide this decision?
Do somatotatin analogues work in this scenario?
Previously untreated
What combination of fluoropyrimidine, PD-1 inhibitor, or trastuzumab do you use?
Are there contraindications to drugs like oxaliplatin or abraxane?
Does chronicity or severity of the patient's underlying symptoms play a role in yo...
KEYNOTE 811 showed improved response rate with the addition of pembrolizumab, but very few patients in this study had low PDL1.
Given multidisciplinary discussion has occurred and SBRT has been agreed upon as local therapy, how do you approach the presence of moderate/significa...
Would you always offer an FGFR inhibitor as second line therapy in these patients instead of a second line chemotherapy regimen?
If an older patient is only fit enough for single agent fluoropyrimidine therapy, would you prefer to give this neoadjuvantly or adjuvantly?
Would you ever consider adjuvant chemotherapy rather than adjuvant immunotherapy after the publication of the CM-577 results? If so, in which pop...
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
If multi-agent systemic therapy, i.e. FOLFIRINOX, is also planned, is there a preferred sequence of therapies?
Would presence of TP53 mutation weigh in on the offer of radiation? Would there be any change expected on the chemo regimen?
Would you recommend 6 months of FOLFOX or just surveillance?
Pathology details: 75% high grade large cell neuroendocrine tumor of the cecum (20-30 mitoses per 10 hpf, Ki67 75%) and 25% adenocarcinoma. Patient ha...
G1 neuropathy and G3 neutropenia were observed with cycle 12 FOLFOX + bev.
Would you reintroduce oxali at a lower dose or switch to irinotecan+EGFRi ...
NCCN recommends perioperative FLOT or FOLFOX vs. neoadjuvant chemoRT with Carboplatin/Paclitaxel or FOLFOX.Does CM-577 and the approval of nivolumab p...
What about for a patient with complete radiographic response who declines surgical management?
If you had a patient with otherwise average risk stage 2 colon cancer but had signet ring or mucinous components to their pathology, would this sway y...
Of note - the tumor tissue biopsy NGS did not show KRAS or BRAF mutations. Microsatellite stable. Patient received first line FOLFOXIRI + Avastin .
For patients who have already undergone trimodality treatment, what time frame do you consider for adjuvant IO?
This involves the primary site responding but progression with new bone marrow involvement with resulting cytopenias.
How do you counsel patients on the benefit of adjuvant therapy who thought surgical resection was curative?
Based on CheckMate 577?Is DFS endpoint sufficient to establish SOC or is OS benefit needed?
Do you worry about fluoropyrimidine resistance with concurrent chemoRT? Is there any role for neoadjuvant immunotherapy?
What factors would influence your approach?
Are there other treatment variations by clinical subsets (eg tumor location, histology, stage II vs III, other biomarkers) seen in CM577 or other data...
CheckMate 577 only included patients with R0 resection.For R1 resections, guidelines suggest observation vs re-resection only.
Do you add on additional cycles of 5-FU/capecitabine to go beyond 3 months of treatment? Or would you stop at 3 months of therapy, dropping the oxalip...
Would the etiology of HCC affect your decision, e.g. non-viral hepatitis since less benefit was shown for this group in IMbrave150?
Ki-67 > 95%, PET-CT negative for any additional disease.
Do you treat with radiation therapy and what dose do you use? What dose do you accept to the duodenum?
Would your decision be influenced by whether a pathologic complete response was attained?
The patient was started on a beta blocker, as this is standard in the area.
Would you consider using infigratinib after progression on pemigatinib?
Colleagues in surgery have raised concerns about post radiation effects in the pelvis with the ordering of short course RT->chemo ->surgery.
Aside from chemoradiation, are there situations in which you might consider this alternate schedule?
What therapy would you offer if the patient had a baseline grade 2 neuropathy?
What determines duration of therapy in patients who achieve stable disease or no evidence of disease on imaging?
Is there any role for radiation in t...
https://pubmed.ncbi.nlm.nih.gov/34077237/
Ampullary carcinoma is not in the NCCN guidelines. Please address not only the role for therapy but the optimal regimen (i.e. Gem based, vs mFOLFIRINO...
Would you extrapolate treatment from the paradigm of anal SCC?
Post-treatment PET/CT and MRI Pelvis at 3 months showed near resolution of iliac and inguinal lymphadenopathy but new avid retroperitoneal lymph nodes...
Colloid is a rare histologic subtype and considered to have more favorable outcomes compared with usual ductal adenocarcinoma, but no dedicated prospe...
Does your decision for 3 vs 6 months of treatment change for low risk stage III colon cancer?
Patients can develop sensory and motor symptoms such as paresthesias, jaw/facial pain and stiffness, cramping and twitching, ptosis and vision changes...
Biopsy of other sites is more consistent with carcinoid tumor.
eg LVI/PNI, poorly differentiated? If so, what regimen and for how long?
Has the recent approval of atezolizumab/bevacizumab impacted your decision making?
Would you recommend radiation, systemic therapy alone, or chemoRT? What about if this recurrence occurred during or shortly after completion of adjuva...
Is there a subset of patients you would avoid neoadjuvant CRT and operate first?
What would you offer in the setting of bulky liver metastases?
This patient had a Ki67 of 27%. However, the inclusion criteria for the NETTER-1 Trial was Ki67<20%. Would Lutathera be an option if labs are withi...
Does it differ in the curative vs palliative setting? Specifically thinking about adjuvant CAPOX in a patient with a BSA of 3. ~400 mg of oxaliplatin ...
Bulky hepatic metastasis
Benefit of oxaliplatin in patients >70 years of age is not proven and only 5FU/capecitabine in a MSI-H tumor is of questionable efficacy. What woul...
Would you use a small cell regimen over a more traditional FOLFOX-esque approach?
Would you offer low dose or standard dose aspirin instead?
Assuming all other factors are favorable (pT1-2, TME, negative margins).
Is there a threshold of when you would use chemo/radiation?
I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...
If you do test, do you have a preferred testing method?
If so, do you avoid pegfilgrastim given that <12 days will lapse between its administration and the next cycle?
Would you favor 2nd line chemo (with or without trastuzumab) versus immunotherapy?
In GEJ or gastric cancers, do you routinely image after surgery, prior to resuming systemic therapy?
If so, how long do you wait after surgery prior to imaging to avoid post-operative findings?
How do you assess the risk of complications from including bevacizumab vs the known benefits of including it with chemotherapy?
Would you try atezolizumab/bevacizumab or switch to a TKI?
i.e. CA 19-9 >100
When would you consider gemcitabine/abraxane as an alternative treatment?
Would chemotherapy alone suffice? Repeat biopsy and EUS were negative for residual disease.
In a patient who is not a surgical candidate, do you offer concurrent carbo/taxol rather than 5FU/oxaliplatin?
What is the risk of perforation / fistulization?
No high risk features such as: lymphovascular invasion, perforation, or involved margins
Does the advent of more effective therapies like peptide receptor radioligand therapy (PRRT) and capecitabine and temozolomide (CAPTEM) dampen enthusi...
Do you use the same high risk factors as adenocarcinoma when deciding on adjuvant treatment for early stage disease?
What parameters do you use to decide to treat beyond progression? Is there any efficacy data from this specific study subgroup in IMbrave150?
Patient with ECOG 0-1
Would you consider adjuvant chemotherapy?
Would you use FOLFIRINOX as in Prodige 23 or FOLFOX as in RAPIDO?
exam is + for ascites
Especially if the patient had advanced N3 disease and is reluctant to pursue surgery?
When would you consider use of ctDNA to help with this decision?
Or would you consider IO agent be given only after progression on platinum + fluoropyrimidine?
If you would elect for adjuvant therapy, which study helps guide your choice of regimen?
The patient went straight to gastrectomy for clinical T1 gastric adenocarcinoma, but post-op was up-graded to T4 disease.
Both ARTIST and Inte...
Patient had a solitary lung metastasis
For example, a FANC mutation
No known cardiac risk factors
Would it make a difference if the VTE diagnosis occurs during bevacizumab therapy or whether it preceded the cancer diagnosis?
The upfront plan is to use a definitive radiation dose of 66 Gy. My reading supports the use of 5FU + cisplatin but another doctor is recommending FOL...
Liver and skeletal metastasis with no disease in the lung.
MRI? Endoscopy? Physical exam?
Is there evidence for radiation therapy in this setting?
What are there most evidence-based options?
What is the added benefit of Chemo-RT vs RT alone?
How would the sidedness of the tumor, BRAF, RAS,HER2 or MSI status affect your decision?
Preferred options in NCCN guidelines: 5FU+cisplatin, 5FU+oxaliplatin, paclitaxel+carboplatin?
Would you consider using PARP Inhibitor in this situation?
Are you placing more weight on patient risk factors such as age >65 or co-morbidities?
Is FOLFOX or 5FU acceptable without XRT if D2 resection?
For a patient not on dialysis? Outside of single agent 5FU, all other standard chemotherapeutic options would be contraindicated for nephrotoxicity.&n...
Would you consider the addition of chemotherapy to proton beam therapy?
Patients oftentimes have cardiac co-morbidities with requirement for anti-coagulation making TKIs, including Bevacizumab, difficult to dose. Would the...
When using short course RT, the NCCN guidelines currently recommend short course RT followed by chemotherapy, followed by surgery. Many surgeons are h...
If so, which patients are the best candidates?
Would you use dual agent chemotherapy such as FOLFIRI, combination of chemo with biologic- IRI/Cetux or all 3 drugs simultaneously? How would sidednes...
Would you continue to trend ctDNA to detect early recurrence?
Upfront surgery vs neoadjuvant therapy? And if neoadjuvant therapy, which regimen?
Patient has a good PS.
Quite often we encounter cholestatic hyperbilirubinemia, wherein GI and IR do not believe ERCP with stents or PTC will alleviate jaundice. If the pati...
Does this also apply to somatic mutations?
Do you routinely test for this with a re-biopsy?
If so, are there particular patient/tumor characteristics that influence your decision?
Would you treat with typical small cell paradigms such as surgery followed by adjuvant platinum doublet +/- radiation vs definitive chemoradiation? Or...
If so, what dose-fractionation regimen do you utilize? What are your target volumes?
Given that majority of benefit is derived from the capecitabine, would this be an acceptable option to decrease patient contact with the healthcare sy...
If so, how much systemic therapy would you give before considering surgery?
What factors other than the Khorana score influence your decision regarding prophylactic anticoagulation in these patients? If prescribing an agent, w...
Would presence of features considered high risk in stage II sway your interpretation of the IDEA trial?
Would you choose to use IO or BRAF directed therapy based on BEACON? Or would you continue to use cytotoxic chemotherapy?
With extensive use of NGS testing, it is commonplace to identify mutations that have no validated therapeutic intervention, but strong biologic signal...
Package insert indicates discontinuing bevacizumab in PE and there are no guidelines on re-challenging after acute clot is managed.
Any adjustments in terms of elective nodal coverage?
In your experience, what approach has been successful to bridge to surgery?
ex. age, surgical risk, and/or performance status
Do you offer EPO and TPO support? Do you modify your systemic therapy up front or after subsequent cycles?
Up to six cycles of treatment were given in the ABC02 trial. Do you offer other treatments if you don't continue gem/cis beyond 24 weeks?
Do you have a similar approach in younger population?
CPS score of 40%. How and when do you incorporate immunotherapy into the treatment of metastatic gastric adenocarcinoma?
Of note, CLASSIC (Noh; Lancet Onc 2014) nor ARTIST (Lee; JCO 2012) evaluated other histologic subtypes, is the approach to treatment any different tha...
In light of the results of the ESPAC-4 trial, is combination gemcitabine plus capecitabine being considered over single agent gemcitabine for adjuvant...
If so, for what platelet count threshold and do you have a preference as to which agent?
In practice, does starting with chemoradiation followed by chemotherapy result in a significant delay in initiating chemotherapy or a patient's abilit...
If so, what agent(s) would you consider given the concurrent amplification and mutation?
Would the presence of peritoneal carcinomatosis change your treatment strategy? If Ki-67 <50%, would you avoid platinum based cytotoxics?
The German trial included patients with tumors up to 16cm from the anal verge, while the Swedish trial update found no local control benefit for tumor...
Given the variable and sometimes indolent disease course of these patients, as well as the absence of a clear overall survival benefit in the PROMID&n...
Would you approach with curative intent with locoregional treatment or systemic treatment alone?
Does the pathology outweigh usual staging and risk factors?
What would be the next line of treatment, PRRT, capecitabine and temozolomide or other?
Is there a "best" way to approach treatment of the viral infection i.e concurrently with therapy, prior to therapy, delayed or post therapy? Does this...
If you do employ this strategy, are there a number of liver lesions (eg <4) or duration of response that guide your decision making?
Would you alter your SBRT dose? How long would you hold the VEGF inhibitor before and after? Does the primary matter (e.g. NSCLC vs. colorectal)?
Instead of FOLFOXIRI and bevacizumab as per TRIBE trial
A number of phase 2 trials support various combinations (e.g. gem/ox, cape/cis, cape/ox, 5-FU based) -- how do you decide either between these regimen...
The NCCN seems to make its recommendation based on extrapolation from colon cancer, but those patients are not treated with pre-op chemoRT.
Do you utilize it immediately following chemoRT or wait until disease progression?
How do you choose between local therapy (surgical debulking or ablation) v. 2nd line systemic therapy? Would you consider immunotherapy?
Would you consider adding trastuzumab to cis/gem in the first line? If not, would you consider adding Her2 directed therapy to FOLFIRI or FOLFOX in th...
Provided the patient can have the solitary met treated definitively with SBRT and is otherwise a good surgical candidate
Do you continue with FOLFIRI for a period and then switch to olaparib (and if so, when do you make that switch) or do you switch directly after FOLFIR...
Does the precise location of duodenal cancer even matter given that treatment would be 5FU/platinum based. Also with the knowledge of impact of sidedn...
On occasion, patients with locally advanced gastric cancer are poor candidates for FLOT-like chemotherapy. Should such patients be taken to surgery up...
In a patient with a good performance status, would you consider this?
PDL1 is > 50%. There was no perforation or lymph node involvement.
I have seen anywhere from 4-6 months utilized. Is there any data to guide your strategy?
Has the utility of BRAF in CRC expanded beyond guiding prognosis? Is there a role in non-metastatic CRC?
Patient characteristics would unarguably be a deciding factor, but outside of these how would you approach the situation?
What are the targets (tumor bed, positive margin, nodes etc.)?
Exploratory analysis of the MAGIC trial suggested perioperative chemotherapy was detrimental in this subset of patients. Has availability of IO altere...
There is some data on TMZ and 5FU based regimens, but convincing evidence is lacking. How would you approach this situation?
I understand the perioperative trials are not based on tumor regression in cancer cells.
For instance, in borderline cases for neoadjuvant therapy (e.g. T2N1 disease), should both be obtained to increase accuracy?
There is increased stroke risk after 65 years of age with bevacizumab. Does that stop you from using it?
KEYNOTE-062 showed deep durable responses are possible with upfront pembro, specifically in the CPS >10 subset, with OS advantage when compare...
For those that do receive adjuvant therapy with stage II disease, we know magnitude of benefit to be lower. If the decision is made to administe...
Do you offer perioperative chemo with metastectomy with an isolated liver metastasis? The RENAISSANCE/AIO-FLOT5 trial (PMID:30448343) is seeking to an...
How do you interpret results when IHC is < 1% but CPS > 1?
For the first treatment day (during combined chemo/XRT courses), is it ok to give XRT first then send the patient for chemo or should the chemo be giv...
When 5FU is a backbone to so many regimens, when (if ever) do you consider re-challenging so as not to abandon an entire line of therapy?
NCCN lists multiple preferred options.
Is there a role for SBRT with or without the addition of systemic therapy?
This is specifically in regards to metastatic colon cancer with good disease control of disease on FOLFOX and preserved hepatic function.
What would be the optimal sequence of surgery, radiation, and chemotherapy for this patient? This patient has an excellent performance status and...
The patient had minimal to no response to neoadjuvant therapy.
What features would make you more likely to recommend radiation therapy with chemotherapy?
Does the presence of BRAF mutation affect your decision?
Do you test for COX-2 and PIK3CA mutations?
Would you offer chemotherapy alone per data from BILCAP or is there any role of radiation?
Does the lack of D2 dissection automatically necessitate adjuvant chemoradiation therapy (ie <5 LN obtained)? Would the presence of high risk facto...
Does the Child Pugh score factor in your treatment decision, i.e. Child Pugh score C?
I have seen favorable clinical trial reports on dasatinib for metastatic disease, but no data on possible adjuvant use. NCCN guidelines suggest ...
What factors do you consider - perforation, size?
For a patient with cT3-4N0 rectal cancer, does the dose of the previous RT affect your decision making (for example, 45 Gy to the pelvis with boo...
Currently, nivolumab is approved as a second line systemic therapy for patients with metastatic HCC with Child-Pugh (CP) A-B7 based on results fr...
How do you approach a decision to retry a previously failed therapy if patient does not wish to pursue a clinical trial? Does sidedness (left or right...
Do you offer chemotherapy upfront in all patients or only if borderline resectable/unresectable? If you treat, what regimen do you use and how l...
What would you consider in the first and second line settings with intact MMR/MSI?
How would being MSI-H/dMMR influence your choice of adjuvant treatment?
Would you switch chemotherapy regimens (i.e if the patient received FOLFOX/Avastin, change to FOLFIRI/Avastin)? Would you treat wuth immunotherapy per...
Would you consider repeating neoadjuvant chemo/RT? Does this, occurring in the context of Lynch Syndrome, change the treatment approach?
does it matter whether it is given frontline vs later?
Does presence of intraperitoneal spread and solitary extraperitoneal visceral metastasis affect management?
Are these patients better candidates for preop chemotherapy alone?
Can you comment based on the results of PRODIGE 24 from ASCO 2018?
http://abstracts.asco.org/214/AbstView_214_218335.html
Would you use this combination in frontline vs later lines of therapy ?
Has the new data with the Natera assay from Reinert T et al in JAMA Oncology May 2019 changed your practice?
Do you start with 1250 mg/m2 BID and then dose reduce based on toxicities? Many studies across varied types of malignancies have shown good tolerabili...
If the patient has large, bulky nodes would you consider starting after chemotherapy for cytoreduction? Or otherwise consider replanning mid-treatment...
Would you consider an aggressive approach such as hepatic resection if the patient is young and has good PS?
What adjuvant options would you consider? chemotherapy? radiation?
5FU/mitomycin C or 5FU/cisplatin? Is there any benefit of cisplatin in terms of skin toxicity?
Would you consider chemotherapy either before or after the lung resection?
Would you consider referring the patient for HIPEC at some point in their treatment, possibly after giving adjuvant chemotherapy, especially if patien...
Is re-challenge with 5-FU safe? Do you consider Capecitabine?
What factors dictate choice of observation versus 6 months of adjuvant peri-operative chemoradiation plus chemotherapy especially if patient did not r...
Taking into account the overlap between treatment regimens for esophageal and gastric cancers, in what clinical context might you feel comfortable tre...
NCCN lists CRT as category 1 but also lists chemotherapy alone as an option. Is this decision based on discussion between surgeon and oncologist...
Specifically, rising levels noted while on somatostatin analogue.
If so, what regimen would you consider?
As in removing the 5-FU bolus from the start of therapy and not because of toxicity?
When will you prescribe 3 v. 6 months of FOLFOX or XELOX for the adjuvant treatment of colon cancer?
The abstract of the pooled meta-analysis is not definitive (JCO 35, 2017: suppl; abstr LBA1), and of the phase III trials (SCOT, TOSCA, Alliance/SWOG ...
If a patient with stage II or III colon adenocarcinoma who presents to your clinic 12-16 weeks after surgical resection do you give adjuvant chemother...
Does HER2 or PD1/PDL1 positivity change first line treatment (i.e. preferential enrollment on clinical trials) or do such patients still receiving sta...
The GTX (gemcitabine, docetaxel, capecitabine) regimen is listed as a category 2B recommendation in the NCCN guidelines- when would this be ...
Since immune check point inhibitors have been approved for GEJ and gastric cancer, would a distal esophogeal adenocarcinoma be considered GEJ or does ...
Would you consider subtotal gastrectomy vs medical therapy?
Most oncologists are comfortable offering FOLFOX for 1st line metastatic adenocarcinoma. Would you be comfortable offering FOLFOX to met. squamous eso...
Is there a change in approach over the past few years? Would there be a role for the 12-gene recurrence score?
NCCN puts "preferred" regimens but only category 1 is cisplatin and fluoropyrimidine. When would you use that regimen over FOLFOX?
For patients receiving adjuvant gemcitabine alone, would you now switch to adjuvant capecitabine alone?
In a patient who developed oligometastatic disease before completing adjuvant XELOX, what treatment(s) and duration of treatment would you recommend?
I have a few patients with kras braf mutation negative metastatic colon cancer treated with upfront FOLFOX- bev followed by 5FU-bev who had regression...
When PDL1 expression is negative, but IHC for mismatch repair expression is consistent with mismatch repair deficiency (MLH2, MSH2, and MSH6 expressed...
NCCN discusses targeted therapies (Everolimus) but also Temodar / Xeloda combination.
Stenting is not possible/not able to bring down the bilirubin level.
Regorafenib has been approved for patients with advanced HCC post-sorafenib, but the benefits are slight and toxicity substantial. Nivolumab has...
What about T3N0 disease? Would you use a recurrence score to help inform decisions?
Given recent FDA accelerated approval of pembrolizumab for MSI-H tumors regardless of site of origin, does it make sense to apply MSI testing, in...
If biopsy of the lesion is consistent with GI origin adenocarcinoma and there are no other sites of disease, would wedge resection followed by adjuvan...
Does your management differ if the hiccups are felt to be related to chemotherapy as opposed to the disease itself?
Tumor involves stomach, liver, and lymph nodes. Pathology is suspicious for sarcomatoid carcinoma, possibly sarcomatoid cholangiocarcinoma.
In LAP07's second randomization (capecitabine+54 Gy vs maintenance gemcitabine +/- erlotinib), 60% of unresectable pancreatic cancer patients who did ...
The pathology shows both adenocarcinoma and neuroendocrine features.
If a patient developed locoregional recurrence after initial chemoradiation, would resection of known disease followed by observation be preferred?
How would the new data presented at ASCO GI 2021 from from Alliance A021501 influence your answer?
Would you use 5-FU and radiation alone? Would your management be different for loco-regional (curative) vs metastatic situations?
If so, how would HIV/Hepatitis status affect you decision?
How do you weigh the recently presented/published data from the NETTER-1 and RADIANT-4 trials in your decision making?
Is salvage liver resection considered the next step in treatment for patients who may have resectable tumors after TACE? If so, do specific tumo...
Reference: https://www.ncbi.nlm.nih.gov/pubmed/23578724
Is MRI being considered the primary mode of imaging in multidisciplinary tumor boards, especially in light of the results of the MERCURY trial (JCO 20...
In your practice, has tumor molecular profiling in pancreatic cancer led to the identification of any actionable targets for which a patient was put o...
Does the location of the pancreatic mass respective to the major vessels alter initial management (surgery, chemotherapy, radiation, or some com...
Do you have a preference for Regorafenib or Lonsurf or do you refer to clinical trials immediately given the known low response rates to these drugs?&...
Would you consider HER-2 directed therapy (lapatinib-trastuzumab)? Does being KRAS-mutated affect your decision?
Would taking the drug at a specific time point prior to their radiation appointment time to maximize blood levels of the drug be clinically beneficial...
Do you treat with standard of care therapy for microsatellite stable (MSS) colorectal cancers or pursue further work-up? Does this differ between adju...
Since some prior subset analyses have suggested that oxaliplatin may not improve outcomes of older patients with colon cancer in the adjuvant settin...
Does the recent Hopkins trial of pembrolizumab change your management of these patients?
If so, what is your preferred regimen?
Should oxaliplatin/capecitabine alone be the standard of care?
In a patient with an R0 resection, would you routinely recommend postop chemoradiation, since these patients were included in the MacDo...
What other molecular tests do you routinely order on such tumors?
Is there a consensus on the MAGIC v. MacDonald debate?
Papers discussed in this category
N Engl J Med, 2006 Jul 6
The New England journal of medicine, 2001-09-06
BMC Cancer, 2015-07-21
Cancer, 2007-11-15
Cancer, 2015-04-01
JAMA, 2012 Jul 11
JAMA, 2008-03-05
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-20
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-08-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-20
International journal of radiation oncology, biology, physics, 2011-09-01
American journal of clinical oncology, 2011-02
International journal of radiation oncology, biology, physics, 2013-12-01
JAMA, 2007 Jan 17
Cancer, 1987 Jun 15
Ann Surg, 2007 Nov
Lancet Oncol., 2017-09-01
J. Clin. Oncol., 2011 Mar 28
Cochrane Database Syst Rev, 2010 Mar 17
J Clin Oncol,
Curr Oncol, 2020 Dec 01
Lancet Oncol, 2020 Feb 26
J. Clin. Oncol.,
Lancet Gastroenterol Hepatol, 2019 Jul 29
J Clin Oncol, 2009 Oct 1
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019-09
N Engl J Med,
Pancreas, 2013-07
Eur J Radiol, 2006 Feb 21
Lancet Oncol., 2015-09-01
JAMA oncology, 2018-01-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-07-01
Lancet Oncol., 2015 Dec 16
Lancet,
JAMA oncology, 2018-06-14
J. Clin. Oncol., 2019 Oct 08
The New England journal of medicine, 1985-06-06
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-11-01
J Can Assoc Radiol, 1981-09-01
J. Clin. Oncol., 1985-03-01
J. Natl. Cancer Inst., 1988-07-20
Ann. Oncol., 2008-09-01
Gastrointestinal cancer research : GCR, 2007-03
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-03-01
N Engl J Med, 2015 Jun 25
Lancet Oncol., 2016-06-01
J Cancer, 2016-01-01
The New England journal of medicine, 2011-02-10
The New England journal of medicine, 2011-02-10
Lancet (London, England), 2016-03-05
The New England journal of medicine, 2017-01-12
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-12-10
Lancet Oncol., 2013-05-01
Oncologist, 2016-12-01
Annals of surgical oncology, 2013-11
N. Engl. J. Med.,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-01-20
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-10
Dis. Colon Rectum, 2014-04-01
Clin Oncol (R Coll Radiol), 2017-04-01
Lancet, 2017-03-11
Can Fam Physician,
Journal of the National Comprehensive Cancer Network : JNCCN, 2014-04
Eur. J. Cancer, 2017-01-01
The British journal of surgery, 2002-11
World journal of gastroenterology, 2010-06-28
Nat. Med., 2016-11-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-12-01
The Lancet. Oncology, 2011-07
Lancet Oncol., 2015-10-01
Oncotarget, 2016-05-31
N. Engl. J. Med., 2004-06-03
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-20
Lancet Oncol., 2019 Mar 25
J. Clin. Oncol., 2019 Feb 01
Pancreas, 2010-08
Br. J. Cancer, 2016-08-09
The New England journal of medicine, 2005-05-05
Clin Cancer Res, 2020 Sep 1
Cancers (Basel), 2020 Jan 14
Clin Cancer Res, 2020 Jan 22
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-12-20
Cancer medicine, 2016-12
N. Engl. J. Med., 2012-05-31
J. Clin. Oncol., 2016-08-10
Lancet Oncol., 2014-07-01
Ann. Oncol., 2014-07-01
J. Clin. Oncol., 2015-10-01
The Annals of thoracic surgery, 2010-09
J. Clin. Oncol., 2009-10-20
Journal of gastrointestinal oncology, 2016-08
The Lancet. Oncology, 2014-10
Lancet, 2010 Aug 19
N Engl J Med, 2020 May 29
J Clin Oncol, 2020 Mar 24
Radiat Oncol, 2014 May 29
Br. J. Cancer, 2014 Aug 28
J Gastrointest Cancer,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-11-01
Lancet Oncol., 2007-09-01
Clin Colorectal Cancer, 2013 Jun 14
Lancet (London, England), 2007-12-15
J. Clin. Oncol., 2009 May 18
Cancer, 2016-01-15
Annals of surgical oncology, 2017-09
Eur J Surg Oncol, 2017 Sep 28
Eur. J. Nucl. Med. Mol. Imaging, 2016 Aug 18
Pancreas, 2016-11
J. Clin. Oncol.,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-03-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-03-20
J Clin Oncol, 2007 Apr 1
J Clin Oncol, 2005 Apr 1
J. Clin. Oncol.,
Lancet,
NEJM Evidence, 2022 Jun 1
Science translational medicine, 2016-07-06
The Lancet. Oncology, 2017-09
Cancer, 2012-06-01
Cancer, 2016-07-01
International journal of radiation oncology, biology, physics, 2016-03-15
J Gastrointest Cancer,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-05-20
Br J Surg,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-03-10
N. Engl. J. Med.,
JAMA Oncol, 2021 Jan 21
Oncol Lett, 2019 Sep 10
J. Clin. Oncol.,
The New England journal of medicine, 2002-10-17
Ann. Surg., 2007-11-01
N Engl J Med, 2021-04-01
J Clin Oncol, 2021 Apr 23
Lancet,
BMC Cancer, 2016 Jul 19
Lancet Oncol., 2013 Oct 11
Lancet (London, England), 2017-01-07
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-02-20
The British journal of radiology, 2017-08
J. Clin. Oncol., 2013 Nov 25
Advances in radiation oncology, 2018
BMJ, 2006 Sep 19
Eur. J. Cancer,
International journal of radiation oncology, biology, physics, 2009-01-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-12-10
BMC Cancer, 2018 Jan 11
J. Clin. Oncol.,
Lancet, 2015 Apr 07
JAMA, 2013 Oct 9
Clin Colorectal Cancer, 2018 Oct 10
Radiation oncology (London, England), 2011-09-28
JAMA surgery, 2019-05-29
J. Clin. Oncol., 2020 Feb 27
BMC cancer, 2017-12-28
JAMA Oncol,
Lancet Oncol., 2016 Jan 26
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-10-20
Cancer,
Eur J Surg Oncol,
Ann. Surg. Oncol., 2010 Sep 21
Clin Epidemiol, 2012 Nov 07
HPB : the official journal of the International Hepato Pancreato Biliary Association, 2016-03
Lancet Oncol., 2018 Apr 09
Lancet, 2019 Apr 11
Ann. Surg. Oncol., 2017 Mar 23
Annals of surgery, 2019-04-05
Nature, 2018-02-08
The Lancet. Oncology, 2019-04
Lancet Oncol., 2017 Nov 02
N. Engl. J. Med.,
Lancet, 2012 Jan 07
Lancet, 2018 Jun 04
Journal of gastrointestinal cancer, 2015-06
Eur. J. Cancer, 2017 May 11
Lancet Oncol., 2014 Feb 18
Ann. Surg.,
JAMA Oncol,
J Clin Oncol, 2012 Jan 20
J. Clin. Oncol., 2019 Sep 12
Sci Rep, 2018 Jun 06
Neuroendocrinology, 2019 Aug 21
Ann. Surg., 2019 Aug 30
J. Hepatol., 2017 Jan 23
The Journal of pathology, 2019-06
N. Engl. J. Med., 2019 Jun 02
Expert Opin Biol Ther, 2019 Mar 27
J. Clin. Oncol., 2019 Oct 14
Lancet Oncol., 2015 Aug 31
Lancet Oncol., 2020 Mar 09
Cancer,
J. Clin. Oncol., 2013 Aug 26
Cancer, 2011-09-01
International journal of radiation oncology, biology, physics, 2015-07-01
Cancer treatment reviews, 2017-02
Strahlenther Onkol, 2019 Feb 08
Radiother Oncol, 2018 Jul 09
Oncologist, 2019 Aug 07
JAMA, 2017-06-20
Annals of oncology : official journal of the European Society for Medical Oncology, 2017-08-01
Lancet Oncol, 2014 Jul 31
J Clin Oncol, 2022 Jun 06
J. Clin. Oncol., 2003 Sep 08
N. Engl. J. Med., 2019 Sep 30
J. Hepatol., 2019 Apr 06
Ann. Surg.,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-04-01
Curr Treat Options Oncol, 2019 Aug 19
J Oncol, 2019 Feb 20
Endokrynol Pol, 2019 Mar 07
J Hepatol, 2021 Nov 19
N Engl J Med, 2020 May 14
J Hepatol, 2021 Dec 11
Clinics in colon and rectal surgery, 2012-06
J. Clin. Oncol., 2019 May 31
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10
Nature, 2017-08-10
Oncogene, 2018 Mar 15
Clin Cancer Res, 2019 Sep 12
JCO Precis Oncol, 2019 Aug 05
Gastroenterology, 2018 May 17
Clin. Gastroenterol. Hepatol., 2018 Nov 28
Hepatology (Baltimore, Md.), 2019-10
JAMA oncology, 2018-05-10
Eur. J. Cancer,
Sci Rep, 2017 Jul 04
JAMA oncology, 2019-06-01
J. Hepatol., 2016-05-01
Eur. J. Cancer, 2011-09-01
Lancet Gastroenterol Hepatol, 2017 Jun 23
Int J Cancer, 2018 Apr 15
JAMA Oncol, 2019 Oct 31
Eur J Surg Oncol, 2014 Oct 07
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-11-01
N. Engl. J. Med.,
Br. J. Cancer,
Int. J. Cancer, 2017 Jun 08
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-01-20
J. Clin. Oncol., 2012-06-01
Annals of surgery, 1999-07
Journal of the National Cancer Institute, 2000-03-01
Diseases of the colon and rectum, 2009-04
Radiother Oncol, 2012 Nov 28
J Gastrointest Oncol,
Radiat Oncol J, 2019 Jun 30
Radiat Oncol, 2019 Jan 16
Radiat Oncol, 2014 Jul 22
Radiat Oncol, 2016 Sep 05
British journal of cancer, 2011-02-01
Anticancer Res.,
The New England journal of medicine, 1994-08-25
N. Engl. J. Med.,
Sci Rep, 2016 May 20
Annals of surgical oncology, 2018-08
JAMA Netw Open, 2020 Feb 05
J. Clin. Oncol., 2015 Nov 16
Lancet Oncol., 2018 Oct 19
Semin. Oncol., 2017 Feb 11
Clinical cancer research : an official journal of the American Association for Cancer Research, 2007-06-15
Seminars in oncology, 2003-08
Annals of oncology : official journal of the European Society for Medical Oncology, 2003-07
Crit Rev Oncol Hematol, 2017 Mar 29
J. Clin. Oncol., 2020 Jan 24
Lancet Oncol., 2020 Mar 02
Clin. Cancer Res., 2018 Jun 27
Biosci. Rep.,
J Natl Compr Canc Netw,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-06-01
Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09
International journal of radiation oncology, biology, physics, 2007-02-01
Annals of surgical oncology, 2015-12
International journal of radiation oncology, biology, physics, 1993-12-01
International journal of radiation oncology, biology, physics, 2017-12-01
Clin Oncol (R Coll Radiol), 2017 Dec 07
J Contemp Brachytherapy, 2019 Feb 28
Eur J Gastroenterol Hepatol,
The Lancet. Oncology, 2015-08
Radiother Oncol, 2020 Mar 30
Ann. Surg., 2020 Mar 20
Lancet Oncol., 2017-03-01
Adv Radiat Oncol, 2020 Apr 22
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005-01
J. Nucl. Med.,
Neuroendocrinology, 2017 Apr 13
J Natl Compr Canc Netw,
Endocr. Relat. Cancer, 2017 Oct 24
Anticancer Res.,
JAMA Oncol, 2020 Dec 10
Cancer, 2018-06-01
Journal of the National Cancer Institute, 2018-11-01
Invest New Drugs, 2012 Oct 09
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-07-10
JAMA oncology, 2019-05-09
JAMA oncology, 2019-05-09
J. Clin. Oncol., 2012 Aug 20
Gut, 2018 Feb 02
Ann. Oncol., 2019 Jun 13
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-04-01
Oncol Lett, 2015 Aug 11
International journal of radiation oncology, biology, physics, 2016-03-15
Cancer medicine, 2019-05
American journal of clinical oncology, 2019-03
Proceedings of the National Academy of Sciences of the United States of America, 2015-11-03
Oncologist, 2020 Mar 10
Semin Diagn Pathol, 2016 Dec 23
Lancet Gastroenterol Hepatol, 2017-07-01
J. Clin. Oncol., 2020 Jun 12
J Surg Oncol, 2019 Jan 12
Ann. Surg. Oncol., 2015 Aug 05
Oncotarget, 2014-11-30
The New England journal of medicine, 2018-12-06
Lancet, 2019 Oct 04
Pancreas,
British journal of cancer, 2005-03-14
Case Rep Oncol, 2020 Jan 21
Lancet Oncol, 2020 Dec 07
Ann Oncol,
Lancet Oncol, 2021 Apr 13
J. Clin. Oncol., 2018 Dec 04
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2011-08
Am. J. Surg., 2013 Jul 01
J Surg Oncol, 2015 Oct 13
Nature, 2013 Aug 14
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-07-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-10-01
Journal of the National Cancer Institute, 2012-02-08
Annals of oncology : official journal of the European Society for Medical Oncology, 2015-04
Cancers (Basel), 2021 Jan 15
ESMO Open,
Lancet Oncol, 2020 Mar 20
J Clin Oncol,
British journal of cancer, 2011-06-07
JAMA oncology, 2018-09-01
Human pathology, 2019-06
Oncoimmunology, 2018
Clinical nuclear medicine, 2015-11
Surgery, 2016-01
J Nucl Med, 2012 Sep 17
Cardiovasc Intervent Radiol, 2019 Oct 23
Eur J Nucl Med Mol Imaging, 2018 Sep 28
Medicine (Baltimore),
Mod Pathol, 2017 Jan 06
Seminars in oncology, 2018-08
Endocrine-related cancer, 2016-09
Pancreas, 2017-07
JAMA Oncol, 2020 Apr 16
Pancreas, 2020 Jan
Surg Oncol Clin N Am, 2020 Oct 20
Scand J Gastroenterol, 2019 Aug 01
J Am Coll Surg, 2017 Jan 11
J Clin Oncol, 2018 Jun 07
Eur J Intern Med, 2008 Jun 10
Pancreas, 2010-08
Annals of surgical oncology, 2006-03
Neuroendocrinology, 2012 Feb 15
Neuroendocrinology, 2015 Sep 10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-07
Gastroenterology clinics of North America, 2018-06
Eur J Cancer, 2015 Jun 08
J Clin Oncol, 2020 Dec 23
Lancet Oncol,
European journal of cancer (Oxford, England : 1990), 2019-01
Blood, 2020 Sep 10
Blood Adv,
The New England journal of medicine, 2018-07-05
Lancet (London, England), 2018-03-24
J Gastroenterol, 2019 Nov 12
Am Heart J, 2010 Sep 18
N Engl J Med,
The Lancet. Oncology, 2019-02
Hepatology, 2019 Oct 14
Cancer cell, 2018-05-14
Annals of oncology : official journal of the European Society for Medical Oncology, 2019-07-01
Lancet Oncol, 2020 Sep 10
JAMA Oncol,
Cancer Discov, 2020 Nov 02
J Gastrointest Oncol,
Hum Mutat,
Ann. Surg. Oncol., 2017 May 30
Gut,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-20
British journal of cancer, 2016-03-29
Pancreatology, 2020 Oct 18
Lancet (London, England), 2016-02-06
European journal of cancer (Oxford, England : 1990), 2019-02
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-06-20
Endocr Relat Cancer,
J Nucl Med, 2018 Aug 16
Eur J Nucl Med Mol Imaging, 2017 Sep 12
International journal of radiation oncology, biology, physics, 2018-09-01
European journal of cancer (Oxford, England : 1990), 2018-01
Seminars in radiation oncology, 1993-01
Radiother Oncol,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-05-15
J Clin Oncol, 2016 Dec 28
CPT Pharmacometrics Syst Pharmacol, 2019 Nov 20
Lancet,
N Engl J Med,
Gastric Cancer, 2013 Feb 28
J Clin Oncol, 2012 May 1
JAMA Oncol,
International journal of radiation oncology, biology, physics, 2011-01-01
Lancet (London, England), 2009-03-07
International journal of radiation oncology, biology, physics, 1989-02
Int J Radiat Oncol Biol Phys,
JAMA oncology, 2018-12-01
Cancer discovery, 2017-03
Ann Oncol, 2020 Nov 20
N Engl J Med, 2018 Mar 29
Hepatology (Baltimore, Md.), 2018-08
Radiology, 2018-06
Hepatology, 2021 Mar 19
J Clin Oncol, 2021 Jun 02
Annals of oncology : official journal of the European Society for Medical Oncology, 2013-11
Int J Radiat Oncol Biol Phys, 2015 Jan 30
J Nucl Med, 2011 Jul 15
BMC Cancer, 2016 May 18
Eur J Cancer, 2021 Apr 29
Am J Transplant, 2016 Jun 09
Transplantation, 2021 Apr 27
Surgery, 2017 Jun 16
J Natl Cancer Inst,
Lancet Oncol, 2021 May 04
The New England journal of medicine, 2009-01-08
Am J Surg, 2020 Aug 16
Eur J Endocrinol, 2013 Apr 15
Jpn J Clin Oncol, 2013 Dec 22
Pancreas,
J Clin Endocrinol Metab,
J Endocrinol Invest, 2018 Jun 09
Br J Radiol, 2018 Mar 20
Eur J Nucl Med Mol Imaging, 2013 Sep 13
BMC Cancer, 2019 Aug 08
Scand J Gastroenterol, 2021 Jan 20
Int J Endocrinol, 2021 Jan 23
Cancer Treat Rev, 2020 Dec 22
JAMA Oncol,
Lancet, 2021 Jun 05
Human pathology, 2016-03
Curr Health Sci J, 2018 Jan 05
Clin Cancer Res, 2020 Mar 6
Int J Radiat Oncol Biol Phys, 2019 Dec 1
Pract Radiat Oncol, 2020 Oct 21
International journal of radiation oncology, biology, physics, 1988-02
Cancers (Basel), 2019 Jul 31
J Am Coll Surg, 2020 Jul 19
Cancer, 2018-02-15
Clin Colorectal Cancer, 2020 Dec 17
Cancer, 2016-09-01
N. Engl. J. Med.,
JAMA Oncol,
Ann Surg, 2021 Jul 16
Seminars in oncology, 2018-08
Pancreas, 2020 Aug
Neuroendocrinology, 2021 Feb 02
Annals of surgery, 2009-05
Annals of surgical oncology, 2019-04
PLoS One, 2021 Mar 26
Lancet Oncol., 2011 May 17
Eur J Surg Oncol, 2021 Jul 31
BMJ Open, 2021 Sep 24
The Lancet. Oncology, 2013-04
Ann Surg,
Int J Radiat Oncol Biol Phys, 2021 Aug 01
J Clin Oncol, 2022 Jan 27
Transpl Int, 2010 May 20
Eur J Surg Oncol,
J Clin Oncol, 2021 Dec 03
Lancet Oncol, 2022 Jan 11
Lancet,
NEJM Evidence, 2022 June 6
Adv Radiat Oncol, 2020 Sep-Oct
Nature, 2021 Dec 15
Br J Cancer, 2021 Feb 03
Hepatogastroenterology, 2013 Jan 16
Medicine (Baltimore),
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-03-10
Brachytherapy, 2018
Oncologist, 2019 Apr
Eur J Cancer, 2022 Feb 21
Lancet Gastroenterol Hepatol, 2022 Feb 01
The New England journal of medicine, 2013-10-31
ESMO Open, 2021 Nov 24
Clin Cancer Res, 2017 Dec 29
Ann Pharmacother, 2021 Jul 20
Ann Transl Med,
Can Fam Physician,
World J Gastroenterol,
Ann Surg, 2021 Aug 13
Ann Surg,
J Clin Oncol, 2020 Mar 02
Nat Med, 2020 Apr 06
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-10-10
JAMA oncology, 2018-03-01
J Clin Oncol, 2015 Nov 02
J Natl Cancer Inst, 2016 Feb 01
Lancet Oncol., 2015-10-01
Eur Respir J, 2017 Oct 12
N Engl J Med, 2022 Jun 05
N Engl J Med, 2022 Jun 04
Int J Radiat Oncol Biol Phys, 2022 Jul 04